News

Jan 06,2021

C4 Therapeutics Announces Key 2021 Milestones to Support Progress Toward Goal of Four Clinical-Stage Programs by Year-End 2022

Dec 17,2020

C4 THERAPEUTICS TO BE ADDED TO THE RUSSELL 2000® AND RUSSELL 3000® INDEXES

Nov 18,2020

Twist Bioscience Ranked 60th Fastest Growing Company in North America on Deloitte’s 2020 Fast 500™

Nov 12,2020

Twist Bioscience, Illumina and Western Digital Form Alliance with Microsoft to Advance Data Storage in DNA

Nov 11,2020

Immune-Onc Therapeutics Announces Orphan Drug Designation of IO-202 (Anti-LILRB4) for Treatment of AML and Poster Presentation at ASH 2020

Nov 10,2020

Aravive to Receive $12 Million Signing Payment, up to an Additional $207 Million in Future Milestone Payments plus Tiered Royalties

Nov 10,2020

Immune-Onc Therapeutics to Present Preclinical Data for IO-108, a Novel Antagonist Antibody Targeting LILRB2 (ILT4) in Solid Tumors, at SITC 2020

No more pages to load

Next page